Healthy volunteers test new drug for brain disease safety
NCT ID NCT06625710
First seen Nov 19, 2025 · Last updated May 01, 2026 · Updated 17 times
Summary
This early-stage study tested the safety of a drug called GV1001 in 59 healthy adults aged 19 to 50. Participants received either a single dose or multiple doses of the drug or a placebo, and were monitored for side effects and how the drug moves through the body. The study does not aim to treat any disease, but to gather important safety information that could support future research into neurodegenerative conditions like Alzheimer's.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEURO-DEGENERATIVE DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Seoul National University Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.